Kaiming Duan

Dr. Kaiming Duan


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Psychiatry Research
Verified
Journal Article
Closed access
JMJia-Hui Ma
Jia-Hui Ma
SWSai-Ying Wang
Sai-Ying Wang
HYHe-Ya Yu
He-Ya Yu
DLDan-Yang Li
Dan-Yang Li
SLShi-Chao Luo
Shi-Chao Luo
KDKaiming Duan
Kaiming Duan

11 July 2023 in Journal of Affective Disorders
Verified
Journal Article
Closed access
SYSi Qi Yang
Si Qi Yang
YZYing Yong Zhou
Ying Yong Zhou
SYShu Ting Yang
Shu Ting Yang
XMXiao Yuan Mao
Xiao Yuan Mao
LCLiang Chen
Liang Chen
KDKaiming Duan
Kaiming Duan

6 January 2018 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
KDKaiming Duan
Kaiming Duan
JMJia-Hui Ma
Jia-Hui Ma
SWSai-Ying Wang
Sai-Ying Wang
ZHZhengDong Huang
ZhengDong Huang
YZYingYong Zhou
YingYong Zhou
HYHeYa Yu
HeYa Yu

14 August 2019 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
HYHe‐Ya Yu
He‐Ya Yu
SWSai‐Ying Wang
Sai‐Ying Wang
CQCheng‐Xuan Quan
Cheng‐Xuan Quan
CFChao Fang
Chao Fang
SLShi‐Chao Luo
Shi‐Chao Luo
KDKaiming Duan
Kaiming Duan

20 May 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YKYun Kuang
Yun Kuang
SWSai-Ying Wang
Sai-Ying Wang
MWMeng-Na Wang
Meng-Na Wang
GYGuo-Ping Yang
Guo-Ping Yang
CGCan Guo
Can Guo
JHJie Huang
Jie Huang
Background: The present study evaluated the safety, pharmacokinetics/pharmacodynamics (PK/PD), and absolute bioavailability (Fabs) of Dex nasal spray in healthy adult subjects, which serves as a bridge for the subsequent study in children.Methods: Part 1: a double-blind, placebo-controlled, single ascending dose study was performed on 48 subjects. For 20-/40-μg groups, every 6/2 subjects received either Dex/placebo nasal spray or Dex/placebo injection in two periods. In total, 12/4 subjects each received 100 μg Dex/placebo nasal spray. Part 2: a randomized, double-blind, placebo-controlled study; 12/4 subjects received 150 μg Dex/placebo nasal spray. Part 3: a randomized, open, self-crossover study; 12 subjects received 20 μg and 100 μg Dex nasal spray in two periods alternately. The method of administration was optimized in Part 2 and Part 3.Results: In part 1, Dex nasal spray was well tolerated up to the maximum dose of 100 μg, whereas the Fabs was tolerated to only 28.9%–32.3%. In Part 2 and Part 3, the optimized nasal spray method was adopted to promote the Fabs of Dex nasal spray to 74.1%–89.0%. A severe adverse event was found in Part 2. In Part 3 (100 μg), the Ramsay score increased the most and lasted the longest, whereas the BIS score decreased most significantly.Conclusion: Using the optimized nasal spray method, a single dose of 20/100 μg of the test drug was safe and tolerable, and 100 μg may have approached or reached the plateau of sedation. In addition, it is found that the optimized method can greatly improve the bioavailability of the test drug, leading to its higher reference value.

2 January 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
YZYingyong Zhou
Yingyong Zhou
ZBZhihong Bai
Zhihong Bai
WZWenchao Zhang
Wenchao Zhang
SXShouyu Xu
Shouyu Xu
YFYunfei Feng
Yunfei Feng
KDKaiming Duan
Kaiming Duan
Importance: Postpartum depression (PPD) is emerging as a major public health problem worldwide. Although the particular period and context in which PPD occurs provides an opportunity for preventive interventions, there is still a lack of pharmacologic prevention strategies for PPD.Objective: To assess the efficacy and safety of dexmedetomidine for prevention of PPD among women with prenatal depression undergoing cesarean delivery.Design, Setting, and Participants: This randomized clinical trial enrolled 338 women who screened positive for prenatal depression at 2 hospitals in Hunan, China from March 28, 2022, to April 16, 2023. Women with an Edinburgh Postnatal Depression Scale score of more than 9 who were 18 years of age or older and were scheduled for elective cesarean delivery were eligible.Interventions: Eligible participants were randomly assigned in a 1:1 ratio to either the dexmedetomidine group or the control group via centrally computer-generated group randomization. Dexmedetomidine, 0.5 μg/kg and 0.9% saline were intravenously infused for 10 minutes after delivery in the dexmedetomidine and control groups, respectively. After infusion, sufentanil or dexmedetomidine plus sufentanil was administered via patient-controlled intravenous analgesia for 48 hours in the control group and dexmedetomidine group, respectively.Main Outcomes and Measures: The primary outcome was positive PPD screening results at 7 and 42 days post partum, defined as a postpartum Edinburgh Postnatal Depression Scale score of more than 9. Analysis was on an intention-to-treat basis.Results: All 338 participants were female, with a mean (SD) age of 31.5 (4.1) years. Positive PPD screening incidence at 7 and 42 days post partum in the dexmedetomidine group vs the control group was significantly decreased (day 7, 21 of 167 [12.6%] vs 53 of 165 [32.1%]; risk ratio, 0.39 [95% CI, 0.25-0.62]; P < .001; day 42, 19 of 167 [11.4%] vs 50 of 165 [30.3%]; risk ratio, 0.38 [95% CI, 0.23-0.61]; P < .001). The dexmedetomidine group showed no significant difference in adverse events vs the control group (46 of 169 [27.2%] vs 33 of 169 [19.5%]; P = .10), but the incidence of hypotension increased (31 of 169 [18.3%] vs 16 of 169 [9.5%]; risk ratio, 2.15 [95% CI, 1.13-4.10]; P = .02).Conclusions and Relevance: Dexmedetomidine administration in the early postpartum period significantly reduced the incidence of a positive PPD screening and maintained a favorable safety profile.Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2200057213